Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Jean‐Marc Schiano de Colella et al.|Blood|2025Cited by 34
Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple MyelomaThomas Chalopin, Salomon Manier, Hélène Demarquette et al.|Blood|2024Cited by 3
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Salomon Manier et al.|Haematologica|2024Cited by 3
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Blood Cancer Journal|2025Cited by 2
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Aurore Perrot, Cyrille Hulin et al.|Blood Cancer Journal|2025Cited by 2